Overview

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Cyclosporine
Cyclosporins
Tacrolimus